SPERO THERAPEUTICS INC's ticker is SPRO and the CUSIP is 84833T103. A total of 96 filers reported holding SPERO THERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is 1.92 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $144,830 | -73.3% | 119,694 | -68.0% | 0.00% | – |
| Q2 2023 | $542,082 | +75504.2% | 373,850 | -24.4% | 0.00% | – |
| Q1 2023 | $717 | -52.7% | 494,541 | -43.6% | 0.00% | -100.0% |
| Q4 2022 | $1,516 | -99.9% | 876,398 | +27.3% | 0.00% | 0.0% |
| Q3 2022 | $1,377,000 | +491.0% | 688,396 | +118.8% | 0.00% | – |
| Q2 2022 | $233,000 | -56.3% | 314,643 | +413.6% | 0.00% | – |
| Q1 2022 | $533,000 | +186.6% | 61,261 | +384.9% | 0.00% | – |
| Q1 2021 | $186,000 | -83.5% | 12,635 | -78.2% | 0.00% | -100.0% |
| Q4 2020 | $1,126,000 | -22.7% | 58,062 | -55.5% | 0.00% | -50.0% |
| Q3 2020 | $1,457,000 | +199.2% | 130,574 | +262.8% | 0.00% | +100.0% |
| Q2 2020 | $487,000 | +327.2% | 35,993 | +156.1% | 0.00% | – |
| Q1 2020 | $114,000 | -6.6% | 14,055 | +10.8% | 0.00% | – |
| Q4 2019 | $122,000 | -25.2% | 12,682 | +11.1% | 0.00% | – |
| Q1 2018 | $163,000 | – | 11,415 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Atlas Venture Associates IX, LLC | 1,376,968 | $17,639,000 | 16.57% |
| Aquilo Capital Management, LLC | 1,054,356 | $13,506,000 | 5.98% |
| VHCP Management II, LLC | 474,015 | $6,072,000 | 1.78% |
| AWM Investment Company, Inc. | 562,296 | $7,203,000 | 1.42% |
| Alphabet Inc. | 1,112,473 | $14,251,000 | 0.74% |
| BVF INC/IL | 460,706 | $5,902,000 | 0.66% |
| DAFNA Capital Management LLC | 70,000 | $897,000 | 0.39% |
| Artal Group S.A. | 600,000 | $7,686,000 | 0.31% |
| Rock Springs Capital Management LP | 525,000 | $6,725,000 | 0.26% |
| Orbimed Advisors | 507,471 | $6,501,000 | 0.10% |